Nektar's Drug Shows Promise in Asthma & Eczema

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded10 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198585

Show notes

Nektar Therapeutics experimental drug, rezpegaldesleukin, showed promising results in improving asthma symptoms for patients with atopic dermatitis. The drug led to significant improvements in asthma control scores after sixteen weeks, with 75% of patients on the highest dose experiencing a clinically important improvement. The study, called REZOLVE-AD, is in its second phase and is expected to provide more long-term data in the first quarter of 2026. Nektar also plans to release data for this drug in treating alopecia areata in December 2025.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.